Clinical Trials Logo

Filter by:
NCT ID: NCT05661266 Recruiting - Multiple Sclerosis Clinical Trials

Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis

Start date: August 16, 2023
Phase:
Study type: Observational [Patient Registry]

The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in multiple sclerosis (MS) patients to further build up a database of MS patients and train a machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.

NCT ID: NCT05660850 Recruiting - Clinical trials for CRC With Atopic Asthma

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Start date: March 22, 2023
Phase: Phase 2
Study type: Interventional

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

NCT ID: NCT05660057 Recruiting - Clinical trials for Post-Concussion Symptoms

Testing of a New Computer Screen for Patients With Persistent Concussion Symptoms (PCS).

Start date: November 7, 2022
Phase: N/A
Study type: Interventional

This study will examine whether a newly designed monitor for computers is better tolerated by concussed patients than the standard computer monitor. The information gathered from this study will contribute to the understanding of the persisting concussion symptoms including computer screen intolerance and photosensitivity, with the aim of helping those with concussions.

NCT ID: NCT05660031 Recruiting - Supraspinatus Tear Clinical Trials

Treatment of the Biceps With Concomitant Supraspinatus Tears

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology. Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Proponents of tenotomy suggest that this is a technically easy procedure that leads to easy rehabilitation and fast return to activity with a low complication and reoperation rate. However, those who support LHB tenodesis list good preservation of elbow flexion and supination strength, improvement of functional scores, elimination of pain, and avoidance of cosmetic deformity as benefits of the procedure. Alternatively, the LHB can be maintained in the joint without tenodesis or tenotomy. In fact, it has not been clearly shown that LHB tenodesis or tenotomy leads to improved outcomes compared to leaving the biceps tendon intact.

NCT ID: NCT05659550 Recruiting - Heart Failure Clinical Trials

Move With Air: Physiological Response Assessment

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

A fan blowing cool air to the face has been shown to alleviate breathlessness in malignant and non-malignant disease at rest and during exercise, however the underlying physiological mechanisms remain unknown. This random order, three-condition design study will explore physiological mechanisms of breathlessness relief with fan-to-face therapy during constant-rate exercise in people with cardiorespiratory disease.

NCT ID: NCT05659498 Recruiting - Clinical trials for Cardiovascular Prevention

Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness

Start date: December 14, 2022
Phase: N/A
Study type: Interventional

The goal of this prospective, randomized trial is to explore the link between cardiovascular disease and mortality in individuals with severe and persistent mental illness (SPMI). The main question it aims to answer is: Is a primary prevention cardiac rehabilitation intervention feasible and effective at reducing cardiovascular risk in people with a primary psychotic disorder or bipolar disorder?" Participants will undergo a multi-component primary prevention intervention program. Researchers will compare with a control group to see if cardiovascular risk reduction is attained.

NCT ID: NCT05659485 Recruiting - Critical Care Clinical Trials

Measuring Family Engagement in Care (The FAME Study)

FAME
Start date: January 31, 2023
Phase:
Study type: Observational [Patient Registry]

There are currently no validated tools to specifically measure family engagement in the intensive care unit (ICU). To address this gap, an interdisciplinary team developed a novel instrument to measure family engagement in the ICU. This will be a prospective observational cohort with an embedded qualitative study to validate the FAMily Engagement (FAME) instrument in the ICU setting. This study will also evaluate the association between family activation, engagement, and family-centred outcomes, and exploring factors (age, relationship, sex, gender, race/ethnicity) that may influence family engagement in the ICU.

NCT ID: NCT05658289 Recruiting - Bone Loss Clinical Trials

Latarjet vs Anatomic Glenoid Reconstruction

Start date: April 24, 2023
Phase: N/A
Study type: Interventional

Anterior shoulder dislocations occur when the humeral head translates anterior to the glenoid cause pain, stiffness, and glenoid bone loss. If left untreated, the risk of recurrence can be up to or greater than 90%. The only surgically modifiable factor to reduce the risk of recurrence is the glenoid bone loss (GBL), where surgeons have the ability to recreate the shape of the glenoid and reduce the risk of recurrent shoulder dislocations. Established boney procedures for shoulder instability include the Latarjet and free bone block procedures, such as the Anatomic Glenoid Reconstruction (AGR). The Latarjet is well known for its lower rate of recurrent instability, but raises concerns due to under-appreciated complications rates. The AGR is a newer surgical approach that has garnered attention for its low rate of recurrent instability and complication profile. Both treatments can reduce pain, increase function following surgery and reduce the risk of recurrent instability. However, these two established approaches have yet to be directly compared and studied on a larger scale. The purpose of this randomized control trial is to compare clinical and radiographic outcomes pre- and post-operatively between the Latarjet to the AGR.

NCT ID: NCT05658276 Recruiting - Cardiogenic Shock Clinical Trials

Establishing Physiologic Outcomes for Ventricular Unloading on VA ECMO

Start date: December 15, 2023
Phase:
Study type: Observational

Aim 1: Prospective, observational analysis of the association between echocardiographic measures of cardiac function and left ventricular unloading on VA ECMO. Aim 2: Prospective, observational analysis of the association between clinical laboratory biomarkers and left ventricular unloading on VA ECMO.

NCT ID: NCT05657912 Recruiting - Clinical trials for Transcatheter Aortic Valve Replacement

Cara CDRS (Conduction Disturbance Risk Score) 1.0

CDRS
Start date: December 12, 2022
Phase:
Study type: Observational

Prospective, non-randomized, multicenter data collection study. Eligible TAVR patients will be enrolled in the study. Cardiac conduction disturbances (CD) requiring permanent pacemaker implantation (PPM) or causing new-onset CD are frequent complications of TAVR that have been shown to be associated with increased mortality and re-hospitalization rates. The purpose of the study is to collect continuous ECG data in order to validate the performance of the Cara Conduction Disturbance Risk Score (CDRS) in patients undergoing transcatheter aortic valve replacement (TAVR). Subjects will be studied during the TAVR procedure and their ECG recordings according to the study schedule below of pre-, during, and after the TAVR procedure up to 14/30 days FU will be collected. 600 patients will be enrolled in this study with the hypothesis that Cara can deliver a statistically significant conduction disturbance risk stratification for patients undergoing TAVR. No investigation intervention is planned during this study. The Cara System analysis will be performed offline.